Ceftriaxone Mylan 2 g inf. sol. (pwdr.) i.v. vial بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceftriaxone mylan 2 g inf. sol. (pwdr.) i.v. vial

viatris gx bv-srl - ceftriaxone disodium 2158,54 mg - eq. ceftriaxone 2000 mg - powder for solution for infusion - 2 g - ceftriaxone (di)sodium - ceftriaxone

Ceftriaxone Mylan 1 g/3.5 ml inj. sol. (pwdr. + solv.) i.m. amp. vial بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceftriaxone mylan 1 g/3.5 ml inj. sol. (pwdr. + solv.) i.m. amp. vial

viatris gx bv-srl - ceftriaxone disodium 1079,27 mg/3,5 ml - eq. ceftriaxone 1000 mg - powder and solvent for solution for injection - 1 g - 3,5 ml - ceftriaxone (di)sodium - ceftriaxone

Ceftriaxone Mylan 500 mg/2 ml inj. sol. (pwdr. + solv.) i.m. amp. vial بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceftriaxone mylan 500 mg/2 ml inj. sol. (pwdr. + solv.) i.m. amp. vial

viatris gx bv-srl - ceftriaxone disodium 539,635 mg/2 ml - eq. ceftriaxone 500 mg - powder and solvent for solution for injection - 500 mg/2 ml - ceftriaxone (di)sodium - ceftriaxone

Ceftriaxone Mylan 500 mg/5 ml inj. sol. (pwdr. + solv.) i.v. amp. vial بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceftriaxone mylan 500 mg/5 ml inj. sol. (pwdr. + solv.) i.v. amp. vial

viatris gx bv-srl - ceftriaxone disodium 539,635 mg/5 ml - eq. ceftriaxone 500 mg - powder and solvent for solution for injection - 500 mg/5 ml - ceftriaxone (di)sodium - ceftriaxone

Ceftriaxone Mylan 1 g inj. sol. (pwdr.) i.v. vial بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceftriaxone mylan 1 g inj. sol. (pwdr.) i.v. vial

viatris gx bv-srl - ceftriaxone disodium 1079,27 mg - eq. ceftriaxone 1000 mg - powder for solution for injection - 1 g - ceftriaxone (di)sodium - ceftriaxone

Ceftriaxone Sandoz 1 g inj./inf. sol. (pwdr.) i.m./i.v. vial بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceftriaxone sandoz 1 g inj./inf. sol. (pwdr.) i.m./i.v. vial

sandoz sa-nv - ceftriaxone disodium 1193,3 mg - eq. ceftriaxone 1000 mg - powder for solution for injection/infusion - 1 g - ceftriaxone (di)sodium - ceftriaxone

Ceftriaxone Sandoz 2 g inj./inf. sol. (pwdr.) i.m./i.v. vial بلجيكا - الإنجليزية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceftriaxone sandoz 2 g inj./inf. sol. (pwdr.) i.m./i.v. vial

sandoz sa-nv - ceftriaxone disodium 2386,6 mg - eq. ceftriaxone 2000 mg - powder for solution for injection/infusion - 2 g - ceftriaxone (di)sodium - ceftriaxone

Ceftriaxone-AFT نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

ceftriaxone-aft

aft pharmaceuticals ltd - ceftriaxone sodium 1.193 g (present as 1.193g ceftriaxone sodium*3.5h2o. eq 1.0793g of ceft. sodium anh or 1g ceftriaxone anh) - powder for injection - 1 g - active: ceftriaxone sodium 1.193 g (present as 1.193g ceftriaxone sodium*3.5h2o. eq 1.0793g of ceft. sodium anh or 1g ceftriaxone anh) - infections caused by pathogens sensitive to ceftriaxone e.g.: · sepsis; · meningitis; · abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); · infections of the bones, joints, soft tissue, skin and of wounds; · infections in patients with impaired defence mechanisms; · renal and urinary tract infections; · respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; · genital infections, including gonorrhoea. · perioperative prophylaxis of infections.

Ceftriaxone-AFT نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

ceftriaxone-aft

aft pharmaceuticals ltd - ceftriaxone sodium 2.385 g (present as 2.385g ceftriaxone sodium*3.5h2o. eq 2.1586g of ceft. sodium anh or 2g ceftriaxone anh) - powder for injection - 2 g - active: ceftriaxone sodium 2.385 g (present as 2.385g ceftriaxone sodium*3.5h2o. eq 2.1586g of ceft. sodium anh or 2g ceftriaxone anh) - infections caused by pathogens sensitive to ceftriaxone e.g.: · sepsis; · meningitis; · abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); · infections of the bones, joints, soft tissue, skin and of wounds; · infections in patients with impaired defence mechanisms; · renal and urinary tract infections; · respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; · genital infections, including gonorrhoea. · perioperative prophylaxis of infections.

Ceftriaxone-AFT نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

ceftriaxone-aft

aft pharmaceuticals ltd - ceftriaxone sodium 596mg (present as 0.596g ceftriaxone sodium*3.5h2o. eq 0.53965g of ceft. sodium anh or 0.5g ceftriaxone anh) - powder for injection - 500 mg - active: ceftriaxone sodium 596mg (present as 0.596g ceftriaxone sodium*3.5h2o. eq 0.53965g of ceft. sodium anh or 0.5g ceftriaxone anh) - infections caused by pathogens sensitive to ceftriaxone e.g.: · sepsis; · meningitis; · abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); · infections of the bones, joints, soft tissue, skin and of wounds; · infections in patients with impaired defence mechanisms; · renal and urinary tract infections; · respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; · genital infections, including gonorrhoea. · perioperative prophylaxis of infections.